Lilly Offloads Baqsimi To Amphastar While Investing In Mounjaro Head-To-Head Trial

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Although Lilly said the glucagon spray’s relatively low sales were not a factor, the pharma may be prioritizing investment on its newer diabetes and weight-loss drug Mounjaro.

Hypoglycemia
Lilly divests glucagon spray product to Amphastar for $500m • Source: Shutterstock

Eli Lilly and Company sold its glucagon rescue therapy Baqsimi to generics/specialty pharma Amphastar Pharmaceuticals, Inc. for $500m up front on 24 April, just days after the Indianapolis pharma drew bigger headlines with the announcement of a head-to-head study testing Mounjaro (tirzepatide) against Novo Nordisk A/S’s Wegovy (semaglutide) in weight loss. Lilly, bullish on the efficacy profile of Mounjaro, may be looking to prioritize its investment in what is expected to be a larger revenue opportunity.

[Sidebar#SC147296]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.